A phase 2 substudy found retatrutide produced dose-related reductions in total body fat mass at 36 weeks versus placebo and dulaglutide in type 2 diabetes. PICO summary and expert commentary.
Browsing: Type 2 Diabetes
Landmark trials and recent evidence on type 2 diabetes management, glucose-lowering therapy, and outcomes.
A post-hoc pooled analysis of three phase 3 trials testing tafolecimab 450 mg every four weeks for LDL-C lowering in Chinese adults with type 2 diabetes and hypercholesterolemia. PICO summary and expert commentary.
A small acute mechanistic crossover study testing whether exenatide-glucagon co-infusion raises myocardial glucose uptake and a diastolic strain-rate marker in eight adults with type 2 diabetes. PICO summary and expert commentary.
A 1-year randomised controlled trial of pharmacist-led collaborative care versus standard care in 400 adults with type 2 diabetes, reporting EQ-5D and visual analogue scale quality-of-life gains alongside a larger HbA1c reduction. PICO summary and expert commentary.
A small single-blind RCT testing whether a family-centered empowerment program improves patient-reported illness acceptance and self-management in type 2 diabetes. PICO summary and expert commentary.
A double-blind placebo-controlled crossover study finds metformin attenuates the postprandial blood pressure fall and reduces postprandial hypotension events in type 2 diabetes, alongside higher GLP-1, slower gastric emptying, and a faster heart rate. PICO summary and expert commentary.
An exploratory post hoc analysis suggesting tirzepatide improves insulin sensitivity more per unit weight loss than semaglutide in type 2 diabetes. PICO summary and expert commentary.
In QWINT-3, once-weekly insulin efsitora alfa was non-inferior to once-daily degludec for HbA1c lowering in basal-insulin-treated type 2 diabetes, with comparable hypoglycaemia. PICO summary and expert commentary.
QWINT-4 phase 3 trial: once-weekly insulin efsitora alfa was non-inferior to daily glargine U100 for HbA1c in basal-prandial-treated type 2 diabetes. PICO summary and expert commentary.
A 10-week whole-food plant-based community programme produced significant between-group weight loss but no significant glycaemic or lipid change in this small New Zealand RCT. PICO summary and expert commentary.